Safety and activity of the investigational agent orteronel (ortl) without prednisone in men with nonmetastatic castration-resistant prostate cancer (nmCRPC) and rising prostate-specific antigen (PSA): Updated results of a phase II study.
暂无分享,去创建一个
M. Michaelson | P. Corn | D. George | M. Hussain | C. Ryan | J. Alumkal | H. Hammers | J. Bruce | Shih-Yuan Lee | S. Moran | P. Mortimer | Shih‐Yuan Lee